Cargando…

Underestimation of N‐glycoPEGylated factor IX one‐stage clotting activity owing to contact activator‐impaired activation

ESSENTIALS: Nonacog beta pegol (N9‐GP) activity can be underestimated in clot method using diverse reagents. Mimicking clotting phase with representative reagents reveals impaired FIX and N9‐GP activation. Polyethylene glycol conjugation amplifies contact activator‐induced decrease in FIX activation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Persson, Egon, La Cour Christoffersen, Carsten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles: Haemostasis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058268/ https://www.ncbi.nlm.nih.gov/pubmed/30046695 http://dx.doi.org/10.1002/rth2.12046

Ejemplares similares

Reagent‐specific underestimation of turoctocog alfa pegol (N8‐GP) clotting activity owing to decelerated activation by thrombin
por: Persson, Egon, et al.
Publicado: (2018)

GlycoPEGylated recombinant factor IX for hemophilia B in context
por: Santagostino, Elena, et al.
Publicado: (2018)

Biodistribution of recombinant factor IX, extended half-life recombinant factor IX Fc fusion protein, and glycoPEGylated recombinant factor IX in hemophilia B mice
por: van der Flier, Arjan, et al.
Publicado: (2023)

Probing activation‐driven changes in coagulation factor IX by mass spectrometry
por: Freato, Nadia, et al.
Publicado: (2021)

F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes
por: Branchini, Alessio, et al.
Publicado: (2021)

Thrombin‐generating potential, plasma clot formation, and clot lysis are impaired in patients with bleeding of unknown cause
por: Hofer, Stefanie, et al.
Publicado: (2019)

Hydrogen‐deuterium exchange mass spectrometry highlights conformational changes induced by factor XI activation and binding of factor IX to factor XIa
por: Bar Barroeta, Awital, et al.
Publicado: (2019)

Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX‐Padua
por: Robinson, Mary M., et al.
Publicado: (2021)

Performance of factor IX extended half‐life product measurements in external quality control assessment programs
por: Nederlof, Angelique, et al.
Publicado: (2020)

Long‐term safety and efficacy of rIX‐FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B
por: Mancuso, Maria Elisa, et al.
Publicado: (2020)

FVIII inhibitors display FV‐neutralizing activity in the prothrombin time assay
por: Arsiccio, Andrea, et al.
Publicado: (2021)

Structure‐function of anticoagulant TIX‐5, the inhibitor of factor Xa‐mediated FV activation
por: Maag, Anja, et al.
Publicado: (2021)

Major bleeding during oral anticoagulant therapy associated with factor V activation by factor Xa
por: Maag, Anja, et al.
Publicado: (2021)

Characterization of interaction between blood coagulation factor VIII and LRP1 suggests dynamic binding by alternating complex contacts
por: Chun, Haarin, et al.
Publicado: (2022)

Extracellular vesicles from amniotic fluid, milk, saliva, and urine expose complexes of tissue factor and activated factor VII
por: Hu, Yong, et al.
Publicado: (2022)

Fusion of engineered albumin with factor IX Padua extends half‐life and improves coagulant activity
por: Lombardi, Silvia, et al.
Publicado: (2021)

Once‐weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8‐GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial)
por: Curry, Nicola, et al.
Publicado: (2019)

A hydrophobic patch (PLVIVG; 1481–1486) in the B‐domain of factor V‐short is crucial for its synergistic TFPIα‐cofactor activity with protein S and for the formation of the FXa‐inhibitory complex comprising FV‐short, TFPIα, and protein S
por: Dahlbäck, Björn, et al.
Publicado: (2022)

Limited factor VIIa surface localization requirement of the factor VIIa–induced overall thrombin generation in platelet‐rich hemophilia A plasma
por: Persson, Egon, et al.
Publicado: (2019)

One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P(®)/Humate P(®) treatment in von Willebrand disease patients
por: de Jager, Nico C. B., et al.
Publicado: (2019)

Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX‐Fc fusion protein: A randomized trial
por: Escuriola Ettingshausen, Carmen, et al.
Publicado: (2019)

Clot stability as a determinant of effective factor VIII replacement in hemophilia A
por: Leong, Lilley, et al.
Publicado: (2017)

Influence of blood group, von Willebrand factor levels, and age on factor VIII levels in non‐severe haemophilia A
por: Rejtő, Judit, et al.
Publicado: (2020)

Blockade of the costimulatory CD28‐B7 family signal axis enables repeated application of AAV8 gene vectors
por: Frentsch, Marco, et al.
Publicado: (2020)

Evaluation of oral factor Xa inhibitor‐associated extracranial bleeding reversal with andexanet alfa
por: Nederpelt, Charlie J., et al.
Publicado: (2020)

The experiences and attitudes of hemophilia carriers around pregnancy: A qualitative systematic review
por: Punt, Marieke C., et al.
Publicado: (2020)

A novel assay for studying the involvement of blood cells in whole blood thrombin generation
por: Wan, Jun, et al.
Publicado: (2020)

Coagulopathy signature precedes and predicts severity of end‐organ heat stroke pathology in a mouse model
por: Proctor, Elizabeth A., et al.
Publicado: (2020)

Management of von Willebrand disease with a factor VIII‐poor von Willebrand factor concentrate: Results from a prospective observational post‐marketing study
por: Goudemand, Jenny, et al.
Publicado: (2020)

Efficacy of pro‐ and anticoagulant strategies in plasma of patients undergoing hepatobiliary surgery
por: Bos, Sarah, et al.
Publicado: (2020)

The direct oral anticoagulants rivaroxaban and dabigatran do not inhibit orthotopic growth and metastasis of human breast cancer in mice
por: Buijs, Jeroen T., et al.
Publicado: (2019)

Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII‐equivalence
por: Leksa, Nina C., et al.
Publicado: (2019)

Thromboelastography‐guided therapy improves patient blood management and certain clinical outcomes in elective cardiac and liver surgery and emergency resuscitation: A systematic review and analysis
por: Dias, João D., et al.
Publicado: (2019)

Temperature‐dependent irreversible conformational change of recombinant ADAMTS13 upon metal ion chelation
por: Rottensteiner, Hanspeter, et al.
Publicado: (2019)

Effect of multidose drug dispensing on the time in therapeutic range in patients using vitamin‐K antagonists: A randomized controlled trial
por: Mertens, Bram J., et al.
Publicado: (2019)

Validity and reliability of the Colorado Adult Joint Assessment Scale in adults with moderate‐severe hemophilia A
por: Funk, Sharon M., et al.
Publicado: (2019)

Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1)
por: Klamroth, Robert, et al.
Publicado: (2019)

Efficacy of fibrinogen concentrate in major abdominal surgery – A prospective, randomized, controlled study in cytoreductive surgery for pseudomyxoma peritonei
por: Roy, Ashok, et al.
Publicado: (2019)

Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants
por: Testa, Sophie, et al.
Publicado: (2019)

Fibrinogen αC‐regions are not directly involved in fibrin polymerization as evidenced by a “Double‐Detroit” recombinant fibrinogen mutant and knobs‐mimic peptides
por: Duval, Cédric, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fnu2a2c9p3c9sutj4ue0hncikq